You are viewing an incomplete version of our website. Please click to reload the website as full version.

V-Akt Murine Thymoma Viral Oncogene Homolog 1 (AKT1) (pSer124) Peptide

Details for Product No. ABIN693937, Supplier: Login to see New
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

Protein Name
Protein Region
Peptide Type Synthetic
Blocking Peptide (BP)
Pubmed 4 references available
Supplier Login to see New
Catalog number from supplier Login to see New
Quantity 0.1 mg
Shipping to United States ( )
Immunogen Synthetic peptide
Specificity The synthetic peptide sequence used to generate the antibody AP3019a was selected from the 117-131 region of human Phospho-AKT1-S124. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Background The serine-threonine protein kinase encoded by the AKT1 gene is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery.
Restrictions For Research Use only
Storage 4
Storage Comment Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles
Expiry Date 6 months
Background publications Kyoung Pyo, Lovati, Pasinetti et al.: "Phosphorylation of tau at THR212 and SER214 in human neuronal and glial cultures: the role of AKT." in: Neuroscience, Vol. 127, Issue 3, pp. 649-58, 2004 (PubMed).

DeBusk, Hallahan, Lin: "Akt is a major angiogenic mediator downstream of the Ang1/Tie2 signaling pathway." in: Experimental cell research, Vol. 298, Issue 1, pp. 167-77, 2004 (PubMed).

LeVea, Reeder, Mooney: "EGF-dependent cell cycle progression is controlled by density-dependent regulation of Akt activation." in: Experimental cell research, Vol. 297, Issue 1, pp. 272-84, 2004 (PubMed).

Bommhardt, Chang, Swanson et al.: "Akt decreases lymphocyte apoptosis and improves survival in sepsis." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 172, Issue 12, pp. 7583-91, 2004 (PubMed).

Catalog No. ABIN693937

Order hotline:

  • +1 877 302 8632
  • +1 888 205 9894 (TF)